Drugs / IRDABISANT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01903824 | Aug → Oct 2013 | cognitive disorder | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRDABISANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1829335 ↗ |
| Known as | CEP-26401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01903824 ↗ |
| Known as | CEP-26401 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1829335 ↗ |
| Known as | IRDABISANT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1829335 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist” CHEMBL1829335 ↗ |
| Modality | Small molecule | — CHEMBL1829335 ↗ |
| Route | Oral | “CEP-26401 as an oral solution” NCT01903824 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL1829335 ↗ |